Niemann-Pick type C (NPC) disease is a cholesterol
Figure 1
NB-DNJ treatment in NPC mice and cats was found to delay the onset dish. In contrast, a 2-week-younger, untreated NPC mouse (9 weeks, of clinical neurological disease, to increase longevity (murine NPC), and 5 days old) is unable to maintain a stable feeding position, falls to the to reduce cellular pathology in the cerebellum. m (applies to all). since the animal maintains itself in a stable position on its feeding motor system dysfunction during its treatment period, Neuropathological changes in NPC disease closely resemble those observed in primary ganglioside storage diseases and the older animal failed to develop ataxia. The four normal cats treated with NB-DNJ (for 19, 23, 54, and 144 [9, 12, 19] ; such changes include the presence of ectopic dendrites on cortical pyramidal neurons and axonal spherdays, respectively) generally weighed less at the end of the treatment period than age-matched, untreated, normal oids on cerebellar Purkinje cells and other GABAergic neurons. The cerebellum is severely impacted in both cats but otherwise appeared healthy. NB-DNJ not only delayed the onset and/or progression of clinical deteriorathe mouse and cat models of NPC and likely gives rise to a significant portion of the clinical phenotype in these tion in mice and cats but also extended the life span of mice (n ϭ 10) from 67 Ϯ 1 day (untreated) to 89 Ϯ 5 models as well as in human disease [9, 12] . To evaluate the effectiveness of NB-DNJ therapy on cerebellar pathology, days (treated), representing a 25% increase in longevity (Figure 1b) .
we used antibodies to Parvalbumin and Calbindin, respec- tively, to evaluate axonal spheroid formation and Purkinje cell loss. In wild-type mice and cats, Parvalbumin-immunoreactivity was detected in Purkinje cells and in the molecular layer, while Calbindin staining was observed in Purkinje cells and their dendrites (Figure 1d ). In feline NPC disease, we previously found that axonal spheroids initially appeared within the neuropil of deep cerebellar nuclei and adjacent white matter and later spread proximally toward Purkinje cell somata prior to the death of these neurons [12] . Purkinje cell axonal spheroids and death correlate with worsening motor system dysfunction in both the cat and mouse models [12, 19] . Consistent with these earlier studies, untreated 9-to 10-week-old NPC mice in the present study displayed an extensive number of Parvalbumin-positive axonal spheroids ( Figure  1d ). In contrast, NB-DNJ-treated NPC mice at this same age showed diminished spheroid formation in the granule cell layer and preserved Purkinje cell architecture to varying degrees throughout the extent of cerebellar folia. Calbindin staining of untreated NPC mice revealed a nearly complete absence of Purkinje cells in many areas of the cerebellum, while NPC mice treated with NB-DNJ exhibited persistence of many of these neurons ( Figure 1d ).
To assess the effectiveness of NB-DNJ in reducing ganglioside storage in NPC brain, we performed high-performance, thin-layer chromatography (HPTLC) [20] and ganglioside immunocytochemistry [9] . HPTLC analysis of NPC-affected brains confirmed GM3 and GM2 ganglioside accumulation in the cerebral cortex of mice and cats with NPC ( Figure 2a) . NB-DNJ treatment resulted in a diminution in ganglioside levels, with notable decreases respectively, GM3 was reduced from 5.3% to 3.0% and GM3 and GM2 gangliosides (upper and lower spots, respectively). from 6.3% to 4.0% of total lipid bound sialic acid, while
Untreated and treated 33-week-old wild-type cats (lanes 1 and 4, respectively), and 9.5-week-old mice (lanes 5 and 9, respectively) GM2 levels were reduced from 2.7% to 1.1% and from exhibit little or no GM3 and GM2 gangliosides, whereas age-4.2% to 2.2% of total lipid bound sialic acid. Previous matched, untreated cats and mice with NPC (lanes 2 and 6, studies in which we used immunocytochemical staining respectively) show increased levels of both of these gangliosides.
to localize GM2 ganglioside in NPC disease revealed that
In comparison, the 33-week-old NPC cat treated with NB-DNJ for 54 days (lane 3) and the two 9.5-week-old NPC mice treated for 6
this ganglioside was elevated in neurons of the cerebral weeks (lanes 7 and 8) exhibited reduced levels of both GM3 and cortex, cerebellum, and other brain regions [9] . For the lyzed. In the cerebral cortex, GM2 immunoreactivity was most conspicuously diminished in pyramidal neurons, while in the cerebellum, GM2 was predominantly rerological disease in murine and feline NPC underscores duced in granule cells (mouse, cat) and in Purkinje cells the importance of glycosphingolipid metabolism and stor-(mouse).
age in the NPC disease cascade and suggests that the inhibition of glycosphingolipid synthesis represents an Our demonstration that NB-DNJ ameliorates clinical neu-effective approach toward therapy for this disorder. Interunrelated to its effect on GLS synthesis, a similar result stemming from the use of a related but more specific estingly, similar approaches directed at lowering cholesterol in NPC disease were reported to have no significant glucosylceramide synthase inhibitor, N-butyl-deoxygalactonojirimycin, or NB-DGJ (14) , on NPC mice (Gondré -impact on clinical neurological progression [21, 22] . NB-DNJ therapy has also recently been shown to effectively Lewis and S.U.W., unpublished data) supports the role for GSLs. Our results are consistent with the view that reduce levels of GM1 ganglioside in circulating leukocytes in human Gaucher disease [23] as well as GM2 ganglioside NPC1 is in some manner linked to ganglioside trafficking or synthesis and that GSLs are centrally involved in the levels and cytopathology in murine Tay-Sachs and Sandhoff diseases [24, 25] . Substrate deprivation has also been NPC pathogenic cascade. Successful amelioration of NPC disease in murine and feline models also suggests that achieved genetically by a cross of Sandhoff disease mice (in which GM2 ganglioside accumulation occurs secondinhibitors of GSL synthesis may be useful in the clinical management of human NPC disease. arily to a deficiency in lysosomal ␤-hexosaminidase) with another line of mice in which the gene for ␤1,4-N-acetylgalactosaminyltransferase (GalNAcT, or GM2 synthase)
Materials and methods
had been ablated [26] . The latter mice lack the ability to Reagents and models produce GM2 and higher-order complex gangliosides.
NB-DNJ (OGT 918; Vevesca) was generously provided by Oxford GlycoSciences. Anti-GM2 ganglioside antibody (1:2,000) was kindly provided
The double mutant animals, in comparison to the mice with Sandhoff disease alone, exhibited significantly less secondarily to the accumulation of GM2 or higher-order glycosphingolipids. In contrast to the Sandhoff-GalNAcT with an AGFA desktop scanner; HPTLC semiquantitative analysis was are also elevated in NPC disease [8, 10, 11] , and of these, done with NIH Imaging 1.62. GM3 and GM2 levels fell within a linear lactosylceramide remained equivalent to NPC-affected range when compared to a calibration curve determined by a scan of brain in the double mutant mice. It is therefore likely known quantities of GM1 ganglioside. Immunocytochemical methods used in these studies were carried out as previously reported [9] .
that the treatment of NPC disease with NB-DNJ in our study is beneficial because it diminishes glycosphingo-
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In summary, we have shown that the glucosyltransferase is conceivable that the beneficial effect of NB-DNJ is
